Fosfomycin clears from your bloodstream relatively quickly, with a plasma half-life ranging from about two to five hours depending on the formulation and how it is measured. But the question most people actually care about is how long the drug remains active where it matters, and that answer is different. After a standard single 3-gram oral dose, urinary concentrations stay high enough to kill most urinary tract pathogens for roughly 24 to 48 hours, and measurable drug can linger even longer. That gap between a short blood-level half-life and a surprisingly long urinary presence is central to understanding why fosfomycin works as a single-dose treatment and when its timeline might shift.
How Fosfomycin Leaves Your Body
Fosfomycin is a small, water-loving molecule that barely binds to proteins in your blood. Your body does almost nothing to break it down. Instead of being metabolized by the liver the way most drugs are, fosfomycin passes through the kidneys essentially unchanged and ends up in your urine. Roughly 95 percent of elimination is renal, driven by glomerular filtration, the passive process by which your kidneys filter blood through tiny capillaries.1PubMed Central. Deciphering pharmacokinetics and pharmacodynamics of fosfomycin No active tubular secretion plays a meaningful role, which means the rate your kidneys filter blood is effectively the rate you clear fosfomycin.2International Journal of Infectious Diseases. The revival of fosfomycin
This simple elimination pathway has practical consequences. Because the drug is not processed by liver enzymes, liver function has little bearing on how long fosfomycin stays in your system. And because the kidneys do all the heavy lifting, anything that changes your kidney filtration rate changes the drug’s timeline proportionally. That makes kidney function the single most important variable in predicting how long fosfomycin will be present in your body.
Blood Levels Versus Urine Levels
When researchers measure fosfomycin in the bloodstream after an intravenous dose, the elimination half-life is about 2.2 hours.3PubMed Central. Fosfomycin kinetics after intravenous and oral administration to human volunteers Oral dosing produces a similar serum half-life of roughly two hours in some studies, though others measuring oral formulations report figures closer to four or five hours in younger adults.4PubMed Central. Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults The variation comes partly from the drug’s distribution into deeper tissues, which creates a slower trickle back into the blood and extends what looks like a longer terminal half-life.
The more clinically relevant number is how long urinary concentrations remain above the threshold needed to inhibit bacteria. After a single 3-gram oral dose of fosfomycin tromethamine, peak urine concentrations appear within about four hours, and levels stay above 128 mg/L for 24 to 48 hours, which is well above the minimum needed to suppress most common urinary tract pathogens.5PubMed. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections In patients being treated prophylactically for recurrent infections, geometric mean urine concentrations remained above an inhibitory threshold on days one, two, and three after both oral and intravenous administration.6Journal of Antimicrobial Chemotherapy. Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection
Why does the drug persist in urine so much longer than in blood? Pharmacokinetic modeling suggests fosfomycin distributes into deeper tissue compartments and then slowly releases back into the bloodstream, feeding a continued trickle into the urine well after peak blood levels have dropped. A three-compartment model, rather than the simpler two-compartment model, better captures this behavior. The practical upshot is that a standard model underestimates how much drug accumulates in urine over time.7PubMed Central. Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection This is exactly why a single oral dose can treat a bladder infection even though the drug seemingly vanishes from the blood within hours.
How Much of the Dose Actually Reaches the Urine
The route of administration makes a big difference. After an intravenous dose, about 80 percent of the drug is recovered in urine within 24 hours. After an oral dose, that figure drops below 25 percent in the same timeframe, largely because oral bioavailability is limited, around 18 to 40 percent depending on the formulation.3PubMed Central. Fosfomycin kinetics after intravenous and oral administration to human volunteers By 48 hours, roughly 37 percent of an oral dose has been excreted in the urine, compared to 74 to 80 percent of intravenous doses.8PubMed Central. Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers Most of the urinary excretion, regardless of route, happens within the first 12 hours.
Oral fosfomycin also comes in two salt forms that behave differently. The tromethamine salt, which is the formulation used in the common single-dose sachet, achieves blood levels two to four times higher than the calcium salt when both are taken on an empty stomach.9PubMed Central. Fosfomycin: Pharmacological, Clinical and Future Perspectives Eating before taking fosfomycin reduces absorption of both forms. This is why the standard advice is to take oral fosfomycin on an empty stomach: higher absorption means more drug reaching the bladder, and a longer window of therapeutic urinary concentration.
Kidney Impairment Dramatically Extends the Timeline
Because fosfomycin depends almost entirely on the kidneys for elimination, reduced kidney function extends the drug’s stay in your system substantially. In people with chronic renal failure, the half-life can climb to around 50 hours, compared to the usual range of two to eight hours in healthy adults.2International Journal of Infectious Diseases. The revival of fosfomycin That is roughly a tenfold increase. One study of hemodialysis patients found a half-life of nearly 49 hours between dialysis sessions, meaning the drug essentially lingered until the next dialysis run removed it.10PubMed. Pharmacokinetics of fosfomycin in hemodialyzed patients
Dialysis itself clears fosfomycin efficiently. During hemodialysis, the drug’s half-life drops dramatically. In patients on prolonged intermittent renal replacement therapy, the half-life fell from about 7.3 hours off-dialysis to 2.5 hours on-dialysis, and the total amount of drug recovered in the dialysate was roughly three quarters of the administered dose.11Journal of Antimicrobial Chemotherapy. Fosfomycin single- and multiple-dose pharmacokinetics in patients undergoing prolonged intermittent renal replacement therapy For someone on dialysis, the timing of fosfomycin dosing relative to dialysis sessions matters: a dose given right before a session may be stripped out before it has a chance to work.
Even milder kidney impairment affects the picture. The drug’s renal clearance correlates with glomerular filtration rate, so someone with moderately reduced kidney function will clear fosfomycin more slowly and carry higher blood levels for longer than someone with normal kidneys.12PubMed Central. Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers The tradeoff is that slower clearance also means less drug reaches the urine per unit of time, which could theoretically reduce efficacy for bladder infections even though the drug stays in the body longer overall.
Age and Body Weight
In older adults, the half-life of oral fosfomycin tromethamine is moderately longer than in younger people, roughly eight hours versus five hours, though the variation between individuals is large. The calcium salt form showed an even more pronounced difference, with an average half-life near 12 hours in elderly subjects. Urinary recovery was also lower in older adults, about 28 percent of the tromethamine dose appearing in urine over 24 hours compared to 58 percent in younger volunteers. Despite these changes, the researchers found that no dose adjustment was necessary for older adults whose kidney function was above a reasonable threshold.4PubMed Central. Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults
Body weight influences how fosfomycin distributes through the body but does not radically change how long it stays. In morbidly obese patients receiving intravenous fosfomycin, peak blood concentrations were lower and the volume of distribution was larger compared to non-obese patients, which makes sense because the drug has more body water to dissolve into.13PubMed. Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial The unbound drug concentration at the target site was about a quarter lower in obese patients. But the overall conclusion from clinical research is that dosing decisions should be guided by kidney function rather than by obesity status alone.14PubMed Central. High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients
What Happens With Repeat Doses
The standard treatment for an uncomplicated bladder infection is a single 3-gram sachet, and for many people that is the only dose they will ever take. But some regimens call for a second dose, usually 72 hours after the first, particularly for more stubborn or recurrent infections. When two 3-gram doses are given three days apart, urinary fosfomycin concentrations stay above the inhibitory cutoff for roughly 161 hours total, which amounts to nearly seven days of urinary coverage from just two doses.15PubMed. Fosfomycin trometamol: multiple-dose regimen for the treatment of lower urinary tract infections
This extended urinary presence after repeat dosing makes sense in light of the tissue-reservoir effect described earlier. Drug already stored in deeper compartments from the first dose continues to leak into the urine, and the second dose reloads those reservoirs. For people wondering whether the drug is “still in their system” after finishing a two-dose course, the answer is that meaningful urinary concentrations likely persist for several days past the last dose, even though blood levels fade much sooner.
Tissue Penetration Outside the Urinary Tract
Fosfomycin is primarily used for urinary infections, and that is where it achieves its highest and longest-lasting concentrations. But the drug does distribute into other tissues, and how well it penetrates matters if it is being considered for infections elsewhere in the body. The evidence here is mixed, and the picture depends on dosing and timing.
Prostate tissue is a good example of the uncertainty. One study attempting to measure fosfomycin in prostate tissue after a standard prophylactic dose was unable to detect any drug at all.16PubMed Central. Serum and Prostatic Tissue Concentrations of Cefazolin, Ciprofloxacin and Fosfomycin after Prophylactic Use for Transurethral Resection of the Prostate A more recent study using a different dosing protocol found a median prostate-to-plasma ratio close to 1.0, meaning fosfomycin reached prostate tissue at concentrations roughly matching blood levels, though individual variation was enormous.17PubMed Central. Population Pharmacokinetics of a Novel Oral Fosfomycin Prophylactic Scheme in the Plasma and Prostate of Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia The difference may come down to timing, dose size, and how samples were collected. The takeaway is that fosfomycin can reach tissues beyond the bladder, but the concentrations and duration at those sites are far less predictable than in urine.
In surgical patients receiving high intravenous doses, fosfomycin penetrated target tissues well in both obese and non-obese individuals, suggesting the drug distributes broadly through body water.14PubMed Central. High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients But for oral fosfomycin at the usual single-dose UTI regimen, serum concentrations are too low to reliably treat infections outside the urinary tract. Blood levels after a 3-gram oral dose peak at only about 7 to 9 micrograms per milliliter, which is modest.3PubMed Central. Fosfomycin kinetics after intravenous and oral administration to human volunteers
The Post-Antibiotic Effect
Even after fosfomycin concentrations drop below the level needed to actively inhibit bacterial growth, the drug’s effects linger. Fosfomycin produces a post-antibiotic effect, a window of time during which bacterial growth remains suppressed after the drug is no longer present at inhibitory concentrations. Against common urinary pathogens like E. coli and Proteus mirabilis, this effect lasts roughly 3.4 to 4.7 hours in laboratory settings, depending on the concentration the bacteria were originally exposed to.18Therapeutics and Clinical Risk Management. Fosfomycin: the characteristics, activity, and use in critical care
This matters because it extends the functional window of the drug beyond what concentration measurements alone would suggest. If urinary fosfomycin levels stay above the inhibitory threshold for 48 hours and then the post-antibiotic effect adds another three to five hours on top of that, the total period of bacterial suppression is somewhat longer than the drug’s measured presence. For a single-dose treatment, every additional hour of suppression helps the immune system finish clearing the infection.
How Fosfomycin Is Measured in the Body
If you are wondering whether fosfomycin would show up on a routine drug screen, the answer is no. Standard drug panels do not look for antibiotics. Detecting fosfomycin requires a dedicated laboratory technique, typically liquid chromatography coupled with tandem mass spectrometry. In clinical studies, the lower limit of detection in plasma is around 0.5 micrograms per milliliter, and in urine it is about 0.05 milligrams per milliliter.19PubMed Central. Fosfomycin Pharmacokinetic Profile in Plasma and Urine and Quantitative Estimation in Prostate and Seminal Vesicles after One and Two Consecutive Doses of Oral Fosfomycin Trometamol in Healthy Male Volunteers These assays are used in research and therapeutic drug monitoring, not in standard clinical practice. Hospitals that monitor fosfomycin levels typically do so only for critically ill patients receiving high-dose intravenous regimens, not for someone who took a single oral sachet for a bladder infection.
The high variability between individuals is worth noting. In a study of healthy women who all received the same oral dose, urinary fosfomycin concentrations varied dramatically from person to person.20Clinical Microbiology and Infection. High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers Some had urine levels several times higher than others at the same time point. This unpredictability means that general statements about “how long fosfomycin stays in your system” are averages, and your personal timeline could be noticeably shorter or longer than the typical range. Kidney function, hydration, body composition, and whether you ate before taking the dose all contribute to that individual variation.
Why Fosfomycin’s Serum Levels Are Deliberately Low for UTI Treatment
A common question people have after reading about fosfomycin’s short blood-level half-life is whether the drug is somehow weak or insufficient. The answer is that the low serum concentrations are a feature, not a bug, at least for bladder infections. The drug concentrates in urine precisely because it passes through the kidneys without being metabolized. Blood is just a transit route. For an uncomplicated lower urinary tract infection, the bacteria live in the bladder, and the drug needs to be in the urine, not the bloodstream. Fosfomycin is essentially designed to wash through the blood and pool where the infection is.
This concentration trick does not work for infections elsewhere in the body, which is why oral fosfomycin at the standard single-sachet dose is not used for kidney infections, bloodstream infections, or deep tissue infections. Intravenous formulations at much higher doses are used in some countries for serious systemic infections, and those achieve far higher blood and tissue levels. But the oral sachet people receive for a straightforward UTI produces blood levels that would be inadequate for anything beyond the bladder and lower urinary tract. If your infection is in the kidneys or has spread to the blood, your doctor will choose a different antibiotic or a different route of fosfomycin administration.